Corrigendum | Open Access
E. Michael Lewiecki, Manuel Diaz Curiel, Joao Lindolfo Borges, Annie Kung, Maria Luisa Brandi, Hans Peter Dimai, "Corrigendum to “New and Emerging Therapies for Osteoporosis”", Journal of Osteoporosis, vol. 2017, Article ID 4175180, 1 page, 2017. https://doi.org/10.1155/2017/4175180
Corrigendum to “New and Emerging Therapies for Osteoporosis”
In the article titled “New and Emerging Therapies for Osteoporosis” , there was an error regarding the FRAX® tool, which should be clarified as follows.
The article notes: “The WHO has also developed a fracture risk assessment tool (FRAX) to estimate the 10-year probability of major osteoporotic fracture (clinical spine, hip, proximal humerus, and distal forearm) and hip fracture, using clinical risk factors for fracture and femoral neck bone mineral density (BMD), if available.” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations . The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.
- E. M. Lewiecki, M. D. Curiel, J. L. Borges, A. Kung, M. L. Brandi, and H. P. Dimai, “New and emerging therapies for osteoporosis,” Journal of Osteoporosis, vol. 2010, Article ID 318320, 2 pages, 2010.
- N. Ford, S. L. Norris, and S. R. Hill, “Clarifying WHO’s position on the FRAX® tool for fracture prediction,” Bulletin of the World Health Organization, vol. 94, p. 862, 2016.
Copyright © 2017 E. Michael Lewiecki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.